Sign In
Buy PJP
$117.60
-0.95 (-0.80%)
At Close: Jul 13, 2026
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?
02:47pm, Thursday, 09'th Jul 2026
Invesco Pharmaceuticals ETF offers a higher dividend yield and lower five-year beta than State Street SPDR S&P Biotech ETF State Street SPDR S&P Biotech ETF holds 155 securities compared to 30 in Inve
Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?
06:04pm, Wednesday, 08'th Jul 2026
Invesco Pharmaceuticals ETF has a higher 5-year growth total of $1,563 compared to $1,480 for First Trust NYSE Arca Biotechnology Index Fund First Trust NYSE Arca Biotechnology Index Fund is more affo
IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?
11:16am, Sunday, 05'th Jul 2026
The iShares U.S. Pharmaceuticals ETF (IHE) charges a lower expense ratio and pays a higher dividend than the Invesco Pharmaceuticals ETF (PJP). IHE is heavily concentrated in its two largest holdings,
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?
04:11pm, Saturday, 04'th Jul 2026
The VanEck Pharmaceutical ETF provides a lower expense ratio and a more substantial dividend yield than the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF delivered higher 1-year total r
State Street Health Care ETF Tops Invesco Pharma on Cost and Size
11:45am, Saturday, 04'th Jul 2026
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio and far greater assets under management than Invesco Pharmaceuticals ETF. Invesco's ETF focuses exclusively o
Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It
05:00pm, Monday, 29'th Jun 2026
Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
07:20am, Monday, 29'th Jun 2026
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?
04:42pm, Monday, 15'th Jun 2026
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
08:45am, Friday, 05'th Jun 2026
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
07:21am, Thursday, 21'st May 2026
The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Biotech Investors Are Tuning Out the MAHA Chaos
05:30am, Wednesday, 20'th May 2026
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
Trump to announce discount drug pricing expansion, White House official says
12:47pm, Monday, 18'th May 2026
U.S. President Donald Trump will announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his administration's pricing deal, on Mond
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
07:21am, Wednesday, 29'th Apr 2026
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.
Could pressure to make money faster kill the next lifesaving pill?
11:27am, Wednesday, 15'th Apr 2026
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
PJP: Healthcare Dashboard For March
05:12am, Tuesday, 17'th Mar 2026
Healthcare subsectors are undervalued as a whole based on 11-year averages. Invesco Pharmaceuticals ETF offers a multi-factor, value-oriented approach to the pharmaceutical industry, outperforming XPH
